Linezolid versus Vancomycin for Prosthetic Joint Infections: a Cost Analysis

Abstract

Home-infusion of vancomycin therapy appears to be the least costly treatment approach for PJIs caused by methicillin-resistant gram-positive bacteria from the perspective of a Hong Kong public health organization.

The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy

“…success rate was > 55%. 24 Conversely, in the third study, i.v. OPAT was found to be less cost-effective than both i.v.…”

“…The patient populations were varied too, including those with surgical site infections, 66 MRSA-complicated SSTIs, 136 cystic fibrosis, 53 febrile neutropenia 65 and prosthetic joint infections. 24 Of the studies identified in the review, only one presented an incremental cost-utility analysis. 65 Using a Canadian health-care provider perspective, the authors in the study found oral antimicrobial treatment at home to be cheaper and less effective than home i.v.…”

“…inpatient therapy. 24,65 In one case, it was also more cost-effective than early discharge with oral therapy and oral outpatient therapy, 65 while in the other its dominance was maintained only when the i.v. success rate was > 55%.…”

Salvage Procedures for Management of Prosthetic Joint Infection After Hip and Knee Replacements

“…However, it is more expensive than vancomycin as a home-infusion therapy. Hence, it is preferable to preserve it for vancomycin resistant cases [28]. …”

New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus

“…Linezolid is a potentially useful drug for the treatment of patients with bone and joint infections due to MRSA. Adverse events associated with long‐term use, such as bone marrow suppression and peripheral neuropathy, are the main issue [93–106].…”